Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

374 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Single tablet regimen with abacavir/lamivudine/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort study.
Baldin G, Ciccullo A, Rusconi S, Madeddu G, Sterrantino G, Freedman A, Giacometti A, Celani L, Latini A, Rossetti B, Cossu MV, Giacomelli A, Lagi F, Capetti A, Di Giambenedetto S. Baldin G, et al. Among authors: madeddu g. Infez Med. 2019 Dec 1;27(4):410-414. Infez Med. 2019. PMID: 31846991 Free article.
The feature of Metabolic Syndrome in HIV naive patients is not the same of those treated: results from a prospective study.
Bonfanti P, De Socio GV, Ricci E, Antinori A, Martinelli C, Vichi F, Penco G, Madeddu G, Orofino G, Valsecchi L, Rusconi S, Menzaghi B, Pocaterra D, Quirino T. Bonfanti P, et al. Among authors: madeddu g. Biomed Pharmacother. 2012 Jul;66(5):348-53. doi: 10.1016/j.biopha.2012.01.005. Epub 2012 Feb 18. Biomed Pharmacother. 2012. PMID: 22705335 Free article.
CD4 cell count and the risk of infective and non-infective serious non-AIDS events in HIV-positive persons seen for care in Italy.
Madeddu G, Monforte AD, Girardi E, Di Biagio A, Lo Caputo S, Piolini R, Marchetti G, Pellizzer G, Giacometti A, Galli L, Antinori A, Lepri AC; ICONA Foundation Study. Madeddu G, et al. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19509. doi: 10.7448/IAS.17.4.19509. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25394018 Free PMC article.
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus.
Mussini C, Lorenzini P, Puoti M, Lichtner M, Lapadula G, Di Giambenedetto S, Antinori A, Madeddu G, Cozzi-Lepri A, d'Arminio Monforte A, De Luca A; ICONA Foundation Study Group. Mussini C, et al. Among authors: madeddu g. PLoS One. 2015 Dec 7;10(12):e0140877. doi: 10.1371/journal.pone.0140877. eCollection 2015. PLoS One. 2015. PMID: 26640953 Free PMC article.
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.
Mocroft A, Lundgren JD, Ross M, Fux CA, Reiss P, Moranne O, Morlat P, Monforte Ad, Kirk O, Ryom L; Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study. Mocroft A, et al. Lancet HIV. 2016 Jan;3(1):e23-32. doi: 10.1016/S2352-3018(15)00211-8. Epub 2015 Nov 17. Lancet HIV. 2016. PMID: 26762990 Clinical Trial.
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients.
Borghetti A, Baldin G, Capetti A, Sterrantino G, Rusconi S, Latini A, Giacometti A, Madeddu G, Picarelli C, De Marco R, Cossu MV, Lagi F, Cauda R, De Luca A, Di Giambenedetto S; Odoacre Study Group. Borghetti A, et al. Among authors: madeddu g. AIDS. 2017 Jan 28;31(3):457-459. doi: 10.1097/QAD.0000000000001357. AIDS. 2017. PMID: 28079545 No abstract available.
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M).
Di Giambenedetto S, Fabbiani M, Quiros Roldan E, Latini A, D'Ettorre G, Antinori A, Castagna A, Orofino G, Francisci D, Chinello P, Madeddu G, Grima P, Rusconi S, Di Pietro M, Mondi A, Ciccarelli N, Borghetti A, Focà E, Colafigli M, De Luca A, Cauda R; Atlas-M Study Group. Di Giambenedetto S, et al. Among authors: madeddu g. J Antimicrob Chemother. 2017 Apr 1;72(4):1163-1171. doi: 10.1093/jac/dkw557. J Antimicrob Chemother. 2017. PMID: 28093483 Clinical Trial.
374 results